32 related articles for article (PubMed ID: 27676469)
1. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Krapf MK; Wiese M
J Med Chem; 2016 Jun; 59(11):5449-61. PubMed ID: 27148793
[TBL] [Abstract][Full Text] [Related]
3. The ABCG2 efflux transporter from rabbit placenta: Cloning and functional characterization.
Halwachs S; Kneuer C; Gohlsch K; Müller M; Ritz V; Honscha W
Placenta; 2016 Feb; 38():8-15. PubMed ID: 26907376
[TBL] [Abstract][Full Text] [Related]
4. The ABCG2 Efflux Transporter in the Mammary Gland Mediates Veterinary Drug Secretion across the Blood-Milk Barrier into Milk of Dairy Cows.
Mahnke H; Ballent M; Baumann S; Imperiale F; von Bergen M; Lanusse C; Lifschitz AL; Honscha W; Halwachs S
Drug Metab Dispos; 2016 May; 44(5):700-8. PubMed ID: 26956640
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence-Based Transport Assays Revisited in a Human Renal Proximal Tubule Cell Line.
Caetano-Pinto P; Janssen MJ; Gijzen L; Verscheijden L; Wilmer MJ; Masereeuw R
Mol Pharm; 2016 Mar; 13(3):933-44. PubMed ID: 26871298
[TBL] [Abstract][Full Text] [Related]
6. Interaction of mammary bovine ABCG2 with AFB1 and its metabolites and regulation by PCB 126 in a MDCKII in vitro model.
Manzini L; Halwachs S; Girolami F; Badino P; Honscha W; Nebbia C
J Vet Pharmacol Ther; 2017 Dec; 40(6):591-598. PubMed ID: 28198024
[TBL] [Abstract][Full Text] [Related]
7. The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
Kraege S; Stefan K; Juvale K; Ross T; Willmes T; Wiese M
Eur J Med Chem; 2016 Jul; 117():212-29. PubMed ID: 27100033
[TBL] [Abstract][Full Text] [Related]
8. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
9. Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates.
Mandíková J; Volková M; Pávek P; Česnek M; Janeba Z; Kubíček V; Trejtnar F
Toxicology; 2013 Sep; 311(3):135-46. PubMed ID: 23856525
[TBL] [Abstract][Full Text] [Related]
10. Jump into a New Fold-A Homology Based Model for the ABCG2/BCRP Multidrug Transporter.
László L; Sarkadi B; Hegedűs T
PLoS One; 2016; 11(10):e0164426. PubMed ID: 27741279
[TBL] [Abstract][Full Text] [Related]
11. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
12. Cobalt Chloride Induces Expression and Function of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Renal Proximal Tubular Epithelial Cell Line HK-2.
Nishihashi K; Kawashima K; Nomura T; Urakami-Takebayashi Y; Miyazaki M; Takano M; Nagai J
Biol Pharm Bull; 2017; 40(1):82-87. PubMed ID: 28049953
[TBL] [Abstract][Full Text] [Related]
13. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
Pires ADRA; Lecerf-Schmidt F; Guragossian N; Pazinato J; Gozzi GJ; Winter E; Valdameri G; Veale A; Boumendjel A; Di Pietro A; Pérès B
Eur J Med Chem; 2016 Oct; 122():291-301. PubMed ID: 27376492
[TBL] [Abstract][Full Text] [Related]
14. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
[TBL] [Abstract][Full Text] [Related]
15. Two Important Anticancer Mechanisms of Natural and Synthetic Chalcones.
Constantinescu T; Mihis AG
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232899
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.
Dei S; Braconi L; Romanelli MN; Teodori E
Cancer Drug Resist; 2019; 2(3):710-743. PubMed ID: 35582565
[TBL] [Abstract][Full Text] [Related]
17. ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning.
Jiang D; Lei T; Wang Z; Shen C; Cao D; Hou T
J Cheminform; 2020 Mar; 12(1):16. PubMed ID: 33430990
[TBL] [Abstract][Full Text] [Related]
18. Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with β
Baltes F; Caspers J; Henze S; Schlesinger M; Bendas G
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668815
[TBL] [Abstract][Full Text] [Related]
19. Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
Köhler SC; Silbermann K; Wiese M
Eur J Med Chem; 2016 Nov; 124():881-895. PubMed ID: 27676469
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
